Is PT-141 FDA Approved? (Regulatory Status Explained)

Most researchers assume PT-141 has blanket FDA approval because it's widely discussed in the literature. That's not accurate. The FDA approved bremelanotide (the formal drug name for PT-141) under the brand name Vyleesi in June 2019. But only for treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women, administered via subcutaneous autoinjector. Every other use. Including all research applications. Operates under a different regulatory framework entirely. The distinction determines sourcing compliance, documentation requirements, and how labs can legally handle the compound.

Our team has worked with research institutions navigating peptide procurement for over a decade. The gap between approved drug product status and research-grade availability creates more compliance confusion than any other peptide in this category.

Is PT-141 FDA-approved for research use?

PT-141 (bremelanotide) is FDA-approved as Vyleesi for treating hypoactive sexual desire disorder in premenopausal women. Not as a research compound. Research-grade bremelanotide must be sourced through suppliers offering material for in-vitro or non-clinical use only, under the Federal Food, Drug, and Cosmetic Act's research exemption (21 CFR 312.2). Labs purchasing bremelanotide for research must document non-clinical intent and cannot use FDA-approved Vyleesi formulations off-label.

Here's the regulatory reality most suppliers won't clarify upfront: the FDA's approval of Vyleesi applies exclusively to AMAG Pharmaceuticals' specific autoinjector formulation for HSDD treatment. It does not grant approval to the molecule itself across all forms, doses, or applications. Research institutions studying bremelanotide's mechanism in neural pathways, comparing melanocortin receptor agonists, or investigating off-label applications cannot procure Vyleesi from clinical channels and repurpose it for lab work. That violates 21 CFR 201.128 and potentially triggers DEA scrutiny if dosing appears recreational. Instead, labs source research-grade bremelanotide from registered peptide manufacturers operating under GMP or ISO certification, labeled explicitly for research purposes only. This article covers the exact FDA classification PT-141 holds, how research sourcing differs from clinical procurement, and what documentation protects labs from compliance violations.

PT-141's FDA Approval: What It Covers (and What It Doesn't)

The FDA approved bremelanotide on June 21, 2019, under New Drug Application (NDA) 210557. The approval is highly specific: subcutaneous injection via prefilled autoinjector, 1.75mg dose administered as needed (minimum 45 minutes before anticipated sexual activity), maximum one dose per 24 hours, for treatment of acquired, generalized HSDD in premenopausal women. That's the scope. The approval does not extend to bremelanotide compounded by pharmacies, bremelanotide in lyophilised powder form, bremelanotide at different doses, or bremelanotide for male subjects. It also doesn't cover intranasal administration. The original PT-141 delivery method tested in Phase IIa trials before Palatin Technologies pivoted to subcutaneous dosing due to transient blood pressure elevation.

Phase III efficacy data came from two randomised, double-blind, placebo-controlled trials (RECONNECT studies) enrolling 1,267 women diagnosed with HSDD using DSM-5 criteria. Primary endpoints measured satisfying sexual events and sexual desire using validated assessment tools. Women receiving bremelanotide demonstrated statistically significant improvements over placebo in both endpoints. The FDA's basis for approval. However, the trials excluded postmenopausal women, men, and subjects with cardiovascular contraindications, which is why the approved indication remains narrowly defined. The drug carries a boxed warning for transient increases in blood pressure and heart rate, with specific contraindications for uncontrolled hypertension and cardiovascular disease.

Research-Grade Bremelanotide: Regulatory Framework and Sourcing Compliance

Research institutions studying bremelanotide. Whether investigating melanocortin-4 receptor modulation, comparing cyclic peptide stability, or mapping downstream neurotransmitter cascades. Cannot legally purchase Vyleesi from distributors and repurpose it for lab work. The Federal Food, Drug, and Cosmetic Act (21 USC 321) and FDA regulations (21 CFR 312.2) distinguish between approved drug products intended for human use and research-grade compounds supplied explicitly for in-vitro, non-clinical investigation. Research-grade bremelanotide must be sourced from peptide manufacturers that label the compound 'for research use only' and provide documentation confirming it is not intended for human consumption, clinical trials without an active IND (Investigational New Drug application), or off-label therapeutic use.

Compliant suppliers operate under Good Manufacturing Practices (GMP) or ISO 9001 certification and provide Certificates of Analysis (CoA) with every batch, confirming purity via HPLC (high-performance liquid chromatography), mass spectrometry, and amino acid sequencing. At Real Peptides, every bremelanotide batch undergoes small-batch synthesis with exact amino-acid sequencing, third-party purity verification, and documentation explicitly stating 'not for human use'. The baseline compliance standard for research procurement. Labs that fail to maintain this documentation risk classification as unlawful human drug distribution if audited by the FDA or state pharmacy boards, particularly if dosing records or study designs suggest human administration without IND coverage.

The Compounded Bremelanotide Question: Legal Status and Risk

Compounding pharmacies in several jurisdictions offer bremelanotide prepared under state pharmacy board oversight, typically marketed for off-label sexual dysfunction treatment in men or postmenopausal women. Uses not covered by Vyleesi's FDA approval. These compounded formulations are legal under the Federal Food, Drug, and Cosmetic Act Section 503A, which allows state-licensed pharmacies to compound medications from bulk API (active pharmaceutical ingredient) for individual patient prescriptions, provided the compound is not 'essentially a copy' of an FDA-approved product. The FDA has not issued formal guidance declaring compounded bremelanotide a direct copy of Vyleesi, so the practice remains in regulatory gray area. Legal at the state level but not federally approved.

For research institutions, compounded bremelanotide introduces compliance risk. Compounding pharmacies prepare medication for human use under prescriber orders. Labs cannot legally procure these formulations and redirect them to non-clinical research without violating federal drug misbranding statutes (21 USC 352). The correct procurement path for research labs remains direct sourcing from peptide manufacturers offering bremelanotide explicitly labeled for research purposes, with CoA documentation confirming the material is not prepared under pharmacy compounding rules or intended for therapeutic use. Our experience working with institutional buyers shows this distinction is frequently misunderstood. Labs assume compounded bremelanotide costs less and carries equivalent compliance, but the regulatory framework governing each pathway is fundamentally different.

PT-141 FDA Approved Status: Clinical vs Research Applications Comparison

What If: PT-141 Procurement and Compliance Scenarios

What If a Lab Purchases Compounded Bremelanotide from a Pharmacy for Research?

This creates immediate regulatory risk. Compounded bremelanotide is prepared under 503A pharmacy rules for human use under individual prescriptions. Repurposing it for non-clinical research violates federal drug misbranding laws (21 USC 352) because the compound was dispensed with therapeutic intent, not research intent. If audited, the lab cannot produce compliant documentation showing non-clinical sourcing, and the pharmacy's compounding records will show human-use preparation. The correct path: source bremelanotide directly from peptide manufacturers offering research-grade material with explicit 'not for human use' labeling and CoA documentation.

What If a Researcher Wants to Study Bremelanotide in Male Subjects?

Vyleesi's FDA approval is limited to premenopausal women with HSDD. Any study involving male subjects, postmenopausal women, or indications beyond HSDD requires an active IND (Investigational New Drug application) filed with the FDA under 21 CFR 312. The IND must include preclinical data, proposed protocol, investigator qualifications, IRB approval, and informed consent documentation. Research-grade bremelanotide sourced for in-vitro or animal work cannot be administered to human subjects without IND coverage. Doing so constitutes unlawful human drug testing and triggers severe FDA enforcement, including clinical hold, Warning Letters, and potential criminal referral.

What If a Supplier Offers Bremelanotide Without a Certificate of Analysis?

Reject the material. Every compliant peptide batch must include a CoA verifying purity via HPLC, confirming molecular weight via mass spectrometry, and documenting amino acid sequence accuracy. Material without CoA documentation cannot be verified for identity, purity, or contamination. Making it unsuitable for any research application where reproducibility and data integrity matter. At Real Peptides, third-party CoA verification is mandatory on every batch, not optional. Labs that skip this step compromise both compliance and experimental validity.

The Blunt Truth About PT-141's Regulatory Status

Here's the honest answer: PT-141's FDA approval is narrower than most researchers realize, and the regulatory framework governing research procurement is stricter than suppliers often disclose. The approval of Vyleesi does not grant blanket legitimacy to bremelanotide across all applications. It authorises one specific formulation for one specific use under one brand name. Every other application, including all research work, operates under different rules that require different sourcing, different documentation, and different compliance standards. Labs that assume 'FDA-approved molecule' means 'unrestricted research access' are setting themselves up for procurement violations, documentation gaps, and regulatory risk that surfaces only during audits or adverse event investigations.

The most common mistake we see: labs purchasing compounded bremelanotide from pharmacies and attempting to use it for non-clinical research. That creates immediate federal misbranding liability because compounded drugs are prepared for human use under pharmacy board rules. Repurposing them for lab work violates the sourcing chain. The second most common mistake: assuming research-grade bremelanotide doesn't require the same CoA rigor as other peptides because 'the FDA already approved it.' The FDA approved Vyleesi. Not the research-grade material your lab is using. Without HPLC verification, mass spec confirmation, and explicit non-clinical labeling, you have no documentation proving what's in the vial.

Our team doesn't sell regulatory shortcuts. We manufacture bremelanotide under small-batch synthesis with exact amino-acid sequencing, third-party purity verification, and explicit 'for research use only' labeling because that's what compliant procurement requires. If a supplier offers cheaper material without CoA documentation or vague labeling that could be interpreted as therapeutic, you're not saving money. You're buying compliance risk. The regulatory distinction between approved drug products and research-grade compounds isn't a technicality. It's the framework that determines whether your lab's procurement holds up under FDA scrutiny.

If the peptide you're buying doesn't come with documentation confirming non-clinical intent, HPLC purity data, and explicit research-use-only labeling, it doesn't meet the baseline compliance standard. Regardless of whether the molecule itself has FDA approval in another formulation. That's not an opinion. That's how 21 CFR 312.2 and federal drug misbranding statutes work. Explore our high-purity research peptides to see what compliant sourcing looks like when documentation and batch integrity aren't optional.

References

Peer-reviewed sources on PT-141 (Bremelanotide) indexed in PubMed, listed for research context. Real Peptides supplies PT-141 (Bremelanotide) for laboratory research use only.

1. Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder. Journal of sex research, 2024. PMID 36809187. doi:10.1080/00224499.2023.2175192
2. An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder. Expert opinion on pharmacotherapy, 2023. PMID 36242769. doi:10.1080/14656566.2022.2132144
3. Bremelanotide for Treatment of Female Hypoactive Sexual Desire. Neurology international, 2022. PMID 35076581. doi:10.3390/neurolint14010006
4. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS spectrums, 2022. PMID 33455598. doi:10.1017/S109285292100002X
5. Safety Profile of Bremelanotide Across the Clinical Development Program. Journal of women's health (2002), 2022. PMID 35147466. doi:10.1089/jwh.2021.0191
6. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. Journal of women's health (2002), 2022. PMID 35230162. doi:10.1089/jwh.2021.0225
7. Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women. Journal of sex research, 2021. PMID 33678061. doi:10.1080/00224499.2021.1885601
8. Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent. Drug and therapeutics bulletin, 2021. PMID 34642243. doi:10.1136/dtb.2021.000020